About EMRELIS

First and only c-Met targeted ADC in 2L+ advanced/metastatic NSq NSCLC with high c-Met protein overexpression1*

Microscopic icon of cancer cells

c-Met protein overexpression can occur in NSCLC, making it a therapeutic target.14

A circular symbol with a slash through DNA

c-Met protein overexpression is distinct from MET gene biomarkers. It is defined by the cell surface protein expression, not a genetic aberration, so it is only detected by IHC, not by genetic tests like NGS or FISH.1,4

Antibody icon

High c-Met protein overexpression is now an actionable biomarker. EMRELIS uses it as an entry point into the cell, where it induces cell cycle arrest and apoptotic cell death.1*

How EMRELIS works to target c-Met protein

A molecular structure showing how EMRELIS works to target non-small cell lung cancer

1

EMRELIS is comprised of the anti-c-Met antibody telisotuzumab conjugated to the cytotoxin MMAE via a protease cleavable linker.1

Chevron arrow pointing right
EMRELIS internalized in the cell

2

EMRELIS targets and binds to c-Met on the cell surface. EMRELIS is then internalized within the cell where it releases the MMAE payload.1†

Chevron arrow pointing right
Apoptotic cell death

3

MMAE disrupts the microtubule network of actively dividing cells, inducing cell cycle arrest and apoptotic cell death.1*†

*EMRELIS may also harm normal cells.15

Occurs in vitro.1

MMAE=monomethyl auristatin E.

Next: